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Abstract
Background: The results of clinical trials have suggested that the thiazolidinedione antidiabetic agents rosiglitazone and
pioglitazone are associated with an increased risk of fractures, but such studies had limited power. The increased risk in
these trials appeared to be limited to women and mainly involved fractures of the arm, wrist, hand, or foot: risk patterns that
could not be readily explained. Our objective was to further investigate the risk of fracture associated with thiazolidinedione
use.
Methods and Findings: The self-controlled case-series design was used to compare rates of fracture during
thiazolidinedione exposed and unexposed periods and thus estimate within-person rate ratios. We used anonymised
primary care data from the United Kingdom General Practice Research Database (GPRD). All patients aged 40 y or older with
a recorded fracture and at least one prescription for a thiazolidinedione were included (n=1,819). We found a within-person
rate ratio of 1.43 (95% confidence interval [CI] 1.25–1.62) for fracture at any site comparing exposed with unexposed periods
among patients prescribed any thiazolidinedione. This association was similar in men and women and in patients treated
with either rosiglitazone or pioglitazone. The increased risk was also evident at a range of fracture sites, including hip, spine,
arm, foot, wrist, or hand. The risk increased with increasing duration of thiazolidinedione exposure: rate ratio 2.00 (95% CI
1.48–2.70) for 4 y or more of exposure.
Conclusion: Within individuals who experience a fracture, fracture risk is increased during periods of exposure to
thiazolidinediones (both rosiglitazone and pioglitazone) compared with unexposed periods. The increased risk is observed
in both men and women and at a range of fracture sites. The risk also increases with longer duration of use.
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The use of thiazolidinedione antidiabetic agents has become
widespread inthetreatmentoftype 2diabetessincetheirintroduction
in the late 1990s, although recently the safety of thisclass of medicines
has been called into question [1–4]. Although most attention has
focused on the possible vascular effects of thiazolidinediones, the
ADOPT trial of rosiglitazone also detected a 2-fold increased risk of
fractures among patients treated with rosiglitazone [5]. Similar effects
were seen in a pooled analysis of pioglitazone trials [6], suggesting a
possible class effect. Surprising—and unexplained—features of the
observed increased fracture risk in clinical trials were that the risk
appeared to mainly involve fractures of the arm, hand, wrist, or foot,
and that the increased risk was restricted to women. However, the
individual clinical trials did not have adequate statistical power to
reliably assess fracture risk. People prescribed and not prescribed
thiazolidinediones are likely to differ in ways that are difficult to
measure and control for, making mostobservational studies subject to
confounding and difficult to interpret. We therefore applied the self-
controlled case-series design (a within-person approach) to assess the
risk of fracture associated with thiazolidinedione use. This approach
eliminates fixed (non-time-varying) between-person confounding,
which is not the case with alternative case-control or cohort designs
[7]. The study was based on primary care computerized clinical
records from the United Kingdom-based General Practice Research
Database (GPRD).
Methods
The General Practice Research Database
The GPRD contains information from over 6 million patients
registered at over 400 computerised general practice surgeries in the
UK [8,9]. Continuous information is recorded for each patient
including a record of each consultation, any diagnoses made, all
prescribed medicines, and basic demographic data. The geographical
distribution and size of GP practices represented in GPRD is largely
representative of the population of England and Wales, and the
individuals registered on the database are representative of the whole
UK population in terms of age and sex [10]. The quality of data held
in the GPRD is subject to rigorous checks and regular audits and it
has been successfully used to conduct over 500 peer-reviewed
published studies. The information obtained from the database is
entirely anonymous. Ethical approval for this study was obtained
from the Independent Scientific Advisory Group of the General
Practice Research Database and the London School of Hygiene and
Tropical Medicine Ethics Committee.
Selection of Participants
Patients were selected from the population registered with the
GPRD up to 4 April 2007. Eligible participants were all those with
both a diagnosis of fracture and a first recorded thiazolidinedione
prescription at least 12 mo after initial registration with the GPRD.
Self-controlled Case-Series Design
The self-controlled case-series design method is derived from rate
modelling using a Poisson distribution and is therefore comparable
with cohort methodology. Only cases are included; thus the
modelling is conditional on people experiencing the outcome in
question (here, diagnosis of fracture) at some stage. It relies on
within-person comparisons in a population of individuals who have
both the outcome and exposure of interest [7,11]. Incidence rate
ratios are derived, comparing the rate of events during exposed
periods of time with the rate during all other observed time periods.
A major advantage of this design is that the potential confounding
effect of both recorded and unrecorded fixed characteristics that
vary between individuals, such as frailty, is removed.
For each participant, we identified all thiazolidinedione prescrip-
tions. The length of exposure following each individual prescription
was calculated using information recorded in GPRD on pack size
and dosing frequency. From all prescription records where this
information was available, the median length of exposure from a
single prescription was calculated. This median duration was
imputed for all individual prescriptions where duration was not
recorded. Thiazolidinedione treatment was assumed to be contin-
uous where any apparent treatment break was less than 60 d, to
allow for partial noncompliance and situations where patients may
have built up treatment stocks. Follow-up time was then censored at
the earliest of any treatment break longer than 60 d or the end of
recorded follow up in the database. A mechanism for thiazolidine-
dione-induced fractures has not yet been established and so it is not
clear whether the influence of thiazolidinediones is short lived or
maintained long after treatment cessation. By censoringfollow up at
a prolonged treatment break we do not make any assumptions
about the duration of influence and therefore avoid bias owing to
misclassification of exposure. The period prior to the first
thiazolidinedione prescription was classified as the baseline,
unexposed period. A representation of exposure periods is shown
in Figure 1.
Recorded fractures were classified according to fracture site
(ankle, arm, chest/rib, face, foot, hand, hip, leg, pelvis, shoulder,
skull, wrist, spine, multiple sites, unknown site). Where more than
one fracture was recorded for a patient, we assumed each fracture
was incident if it occurred at a different site to the previous fracture,
or was recorded more than 6 mo after a fracture at the same site.
Analysis using the self-controlled case-series design inherently
takes duration of follow up into account. We estimated relative
rate ratios for fracture using conditional Poisson regression with
Stata Version 9 software (StataCorp), adjusting for age at first
thiazolidinedione prescription in 1-y bands. We first assessed the
impact of exposure to any thiazolidinedione on fracture at any site.
We also looked for evidence of sex differences, the differential
effects of rosiglitazone and pioglitazone, the effect of thiazolidine-
dione exposure duration, and the effect on fractures at specific
sites: (1) arm, wrist, hand, and foot; (2) hip; (3) spine.
For validation purposes we also assessed the association between
treatment with a sulphonylurea and fracture at any site as we had
no a priori reason to suspect an association. The same study
population was used, but exposed periods were defined as periods
where the patient was receiving any sulphonylurea. For this
analysis, follow up was censored at the date of first thiazolidine-
dione prescription.
Results
We identified 1,819 patients in the GPRD prescribed at least
one thiazolidinedione and with a record of at least one fracture
and background details for these patients are shown in Table 1.
1,356 patients received only prescriptions for rosiglitazone, 389
received only pioglitazone, and the remaining 74 received
prescriptions for both rosiglitazone and pioglitazone at different
times. 990 (54%) were female and the mean age at first
thiazolidinedione exposure was 57.9 y for men and 65.4 y for
women. The mean duration of unexposed follow up prior to
thiazolidinedione use was 9.5 y, and the mean duration of
exposure to a thiazolidinedione was 2.3 y. Arm, foot, wrist, or
hand fractures were recorded for 905 patients, hip fractures for
150 patients, and spine fractures in 66 patients. The remaining
733 patients had fractures at other sites. Patients with hip and
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prescription: mean age of 70.5 y and 65.6 y for patients with
hip and spine fractures, respectively. Regarding multiple fractures,
283 (16%), 64 (4%), and 25 (1%) had two, three, and four or more
fractures, respectively.
Absolute rates of fracture are uninformative in this study since
selection is restricted by design to patients who have had a
fracture. The crude rate ratio for any fracture at any site,
comparing thiazolidinedione exposed versus unexposed period
was 1.70 (95% confidence interval [CI] 1.53–1.88), but this does
not take into account the fact that each participant is older in the
exposed period. We detected an annual increase in the rate of all
fractures of approximately 5% when the effect of age was
considered alone (rate ratio for a 1-y increase in age=1.05, 95%
CI 1.04–1.06). After adjustment for age in single year bands, the
adjusted rate ratio for the association between thiazolidinediones
and fracture was 1.43 (95% CI 1.25–1.62) comparing exposed
with unexposed periods (Table 2). There was no evidence that the
association varied by sex; the age-adjusted rate ratio for all fracture
types amongst patients receiving any thiazolidinedione was 1.42
(1.20–1.69) for females and 1.44 (1.18–1.77) for males. When
thiazolidinedione exposure was stratified by duration, the rate
ratio for all fractures increased steadily from 1.26 (1.07–1.47)
during the first year to 2.00 (1.48–2.70) during years four to seven.
Fracture-site specific analyses for all thiazolidinedione users
revealed a rate ratio of 1.28 (1.05–1.56) for arm, wrist, hand, or
foot fractures, 2.09 (1.29–3.40) for hip fractures, and 2.72 (1.29–
5.73) for spine fractures. There was no evidence that the rate ratio
varied by gender. In patients who only received rosiglitazone, the
rate ratio for fracture at any site was 1.49 (1.28–1.74), and
amongst those who only received pioglitazone the rate ratio was
1.26 (0.95–1.68) (Table 3). A test for interaction showed no
evidence that the effect varied by thiazolidinedione type (p=0.47).
The rate ratios for fractures at specific sites were also similar for
each thiazolidinedione (Table 3).
Bias can be introduced to a self-controlled case-series analysis if
follow up is curtailed because of the event of interest in a
substantial number of cases (e.g., due to a fatal outcome). For this
reason a sensitivity analysis was performed for any fracture at any
site, excluding patients who died during their observation period
(n=155). The rate ratio for thiazolidinedione exposed versus
unexposed periods in this subgroup was 1.39 (1.21–1.59).
Fracture-site specific analyses also yielded very similar results
when patients who died were excluded.
A series of further sensitivity analyses were conducted: (1)
censoring follow up in November 2006, prior to publication of the
ADOPT study results highlighting fractures as a possible risk with
rosiglitazone [5]; (2) restricting follow up to 2000 onwards, when
Figure 1. Representation of study design. The figure illustrates a single individual prescribed a thiazolidinedione during their observation
period. All participants included in the analysis had at least one prescription for a thiazolidinedione and at least one fracture. The rate ratios presented
are pooled estimates derived from the rate of events during the risk (exposed) periods divided by the rate of events during the baseline periods. Age
is adjusted for at all stages of the analysis.
doi:10.1371/journal.pmed.1000154.g001
Table 1. Demographic details of study population.
Patient Group
n Patients with at
least One Fracture
at Any Site
Mean Age at Start
of Glitazone
Exposure (y)
a
n Fractures
before Glitazone
Exposure
b
Duration (mean y) of
Follow up Pre-Glitazone
Exposure
a
n Fractures during
Glitazone Exposure
b
Duration (Mean
y) of Glitazone
Exposure
a
Any glitazone 1,819 62.0 (12.8) 1,546 9.5 (4.6) 720 2.3 (1.7)
Female 990 65.4 (12.1) 825 9.2 (4.6) 445 2.4 (1.7)
Male 829 57.9 (12.3) 722 9.8 (4.6) 274 2.3 (1.7)
Rosiglitazone only 1,356 62.2 (13.0) 1,138 9.4 (4.6) 542 2.3 (1.7)
Pioglitazone only 389 61.7 (12.3) 347 9.6 (4.5) 149 2.3 (1.6)
aStandard deviation given in parentheses.
bSome patients had more than one fracture.
doi:10.1371/journal.pmed.1000154.t001
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analysis to 2 y prior to and post first thiazolidinedione prescription.
These three sensitivity analyses had no material effect on ourresults.
Theself-controlledcase-seriesanalysiswasrepeatedusingthesame
study population, but measuring the association between all fracture
types and exposure to sulphonylureas rather than thiazolidinediones
(Table 4). 694 relevant patients were identified and the rate ratio for
fracture at any site amongst all patients prescribed a sulphonylurea
was 0.84 (0.66–1.08). There was no evidence that the association
varied with sulphonylurea exposure duration up to 7 y.
Discussion
In these data we have found an increased risk of fracture in
users of thiazolidinediones. Our results suggest that the increased
risk applies to both men and women and is observed at a wide
range of fracture sites. In addition, we were able to look at the
effects of treatment duration on fracture risk, and our results
suggest the risk may increase steadily with exposure duration up to
7 y. The risk estimate with pioglitazone was comparable to that
seen with rosiglitazone at each fracture site, although the results
for pioglitazone failed to reach statistical significance given that
relatively fewer patients registered in the GPRD receive
pioglitazone. While a clear mechanism for a deleterious effect of
thiazolidinediones on bone has not been identified, a recent review
has highlighted a number of preclinical studies in which
rosiglitazone was associated with an increase in bone loss [12].
A key advantage of this study was the use of the self-controlled case-
series design, which is much less prone to problems of confounding
than traditional case-control or cohort designs. Between-patient
differences are of little relevance since the risk comparisons are made
entirely within patients. Also, the self-controlled case series is often
Table 2. Case-series analysis for thiazolidinediones: association between exposure to any thiazolidinedione and fractures.
Fracture Site Exposure Patient Years n Fractures
Age-Adjusted Rate Ratio for
Fracture (95% CI
Fracture at any site
All patients (n=1,819) Unexposed periods 17,221 1,546 Baseline
Exposed periods (all) 4,240 720 1.43 (1.25–1.62)
Thiazolidinedione exposure period
a 0–1 y (n=1,819) 1,600 235 1.26 (1.07–1.47)
1–2 y (n=1,325) 1,087 179 1.49 (1.24–1.79)
2–3 y (n=874) 714 127 1.70 (1.37–2.12)
3–4 y (n=564) 446 104 2.31 (1.80–2.97)
4–7 y (n=342) 392 75 2.00 (1.48–2.70)
Females (n=990) Unexposed periods 9,103 824 Baseline
Exposed periods 2,357 446 1.42 (1.20–1.69)
Males (n=829) Unexposed periods 8,118 722 Baseline
Exposed periods 1,883 274 1.44 (1.18–1.77)
Foot, arm, wrist, or hand fracture
All patients (n=905) Unexposed periods 8,599 735 Baseline
Exposed periods 2,102 284 1.28 (1.05–1.56)
Females (n=519) Unexposed periods 4,837 411 Baseline
Exposed periods 1,227 183 1.26 (0.98–1.62)
Males (n=386) Unexposed periods 3,762 324 Baseline
Exposed periods 876 101 1.28 (0.93–1.77)
Hip fracture
All patients (n=150) Unexposed periods 1,317 71 Baseline
Exposed periods 394 87 2.09 (1.29–3.40)
Females (n=105) Unexposed periods 862 45 Baseline
Exposed periods 280 66 2.09 (1.17–3.72)
Males (n=45) Unexposed periods 456 26 Baseline
Exposed periods 113 21 1.90 (0.74–4.91)
Spine fracture
All patients (n=66) Unexposed periods 624 41 Baseline
Exposed periods 155 29 2.72 (1.29–5.73)
Females (n=34) Unexposed periods 311 21 Baseline
Exposed periods 82 15 2.34 (0.77–7.13)
Males (n=32) Unexposed periods 313 20 Baseline
Exposed periods 73 14 3.53 (1.18–10.58)
aTest for trend (p,0.01).
doi:10.1371/journal.pmed.1000154.t002
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and so more precise estimates of effects can be made.
Other main strengths of the study were that it was large and
statistically powerful. Our study was based on routine clinical data
from the UK GRPD, which is representative of the population of
the UK and so the results are likely to be highly generalisable. The
validity of fracture recording in the GPRD has been shown to be
high, and drug-related fractures have been the subject of several
studies within this database [13–15]. A potential weakness might
relate to the quality of the clinical data. Drug prescriptions in the
GPRD are generated by practice computers, ensuring the
accuracy of the electronic prescribing records. Prescription data
were highly detailed and recorded prior to people developing
fracture so there was no potential for recall bias. It is possible that
some patients were not taking their prescribed thiazolidinediones
during periods we assigned as exposed; however, we believe the
likelihood of widespread low adherence in patients with a serious
illness such as diabetes is unlikely and this would tend to dilute any
true effect estimate for thiazolidinedione exposure.
We also acknowledge there are inherent difficulties in
determining whether a recorded diagnosis in the GPRD is truly
incident or a repeat record of a previous diagnosis. We aimed to
do this by excluding from the analysis all fractures occurring
within 6 mo of a previous fracture at the same site. This approach
Table 3. Case-series analysis for thiazolidinediones: association between exposure to specific thiazolidinediones and fractures.
Fracture Site Exposure Patient Years n Fractures Age-Adjusted Rate Ratio for Fracture (95% CI)
Fracture at any site
Rosiglitazone (n=1,356) Unexposed periods 12,772 1,139 Baseline
Exposed periods 3,180 543 1.49 (1.28–1.74)
a
Pioglitazone (n=389) Unexposed periods 3,747 347 Baseline
Exposed periods 892 149 1.26 (0.95–1.68)
a
Foot, arm, wrist, or hand fracture
Rosiglitazone (n=675) Unexposed periods 6,446 539 Baseline
Exposed periods 1,564 211 1.30 (1.03–1.64)
Pioglitazone (n=188) Unexposed periods 1,748 158 Baseline
Exposed periods 446 61 1.43 (0.92–2.22)
Hip fracture
Rosiglitazone (n=115) Unexposed periods 1,004 56 Baseline
Exposed periods 310 66 1.80 (1.03–3.15)
Pioglitazone (n=32) Unexposed periods 282 13 Baseline
Exposed periods 75 20 2.65 (0.81–8.70)
Spine fracture
Rosiglitazone (n=53) Unexposed periods 492 33 Baseline
Exposed periods 132 24 3.13 (1.35–7.21)
Pioglitazone (n=11) Unexposed periods 107 7
Exposed periods 18 4 *
Patients exposed to both thiazolidinediones excluded.
aTest for interaction (p=0.47).
*Insufficient outcomes to calculate rate ratio.
doi:10.1371/journal.pmed.1000154.t003
Table 4. Case-series analysis for sulphonylureas: association between exposure to any sulphonylurea and fractures.
Fracture at Any Site Exposure Patient Years n Fractures Age-Adjusted Rate Ratio for Fracture (95% CI)
All patients (n=694) Unexposed periods 4,117 490 Baseline
Exposed periods (all) 2,408 348 0.84 (0.66–1.08)
Sulphonylurea exposure
period
a
0–1 year (n=694) 597 102 0.89 (0.69–1.16)
1–2 y (n=520) 460 61 0.77 (0.56–1.05)
2–3 y (n=405) 357 53 0.94 (0.67–1.31)
3–4 y (n=305) 267 43 1.09 (0.76–1.59)
4–7 y (n=243) 465 62 1.01 (0.71–1.43)
aTest for trend p=0.50; sum of patient years and number of fractures in analysis stratified by exposure duration is less than in the main analysis as follow up censored at
7 y in stratified analysis.
doi:10.1371/journal.pmed.1000154.t004
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and so we conducted a sensitivity analysis where only the first ever
fracture recorded for each patient was included. This made no
material difference to our results.
The validity of the self-controlled case-series method relies on the
independence of the decision to initiate treatment and the risk of the
outcome. For this study, it requires that the decision to prescribe a
thiazolidinedioneis independent ofwhether a patienthasever had a
fracture and their perceived risk of having a fracture at a later date.
It also assumes the decision to start a thiazolidinedione is not
temporally correlated with other exposures that influence the risk of
fractures (e.g., corticosteroid therapy). If these assumptions are
invalid, the results presented here could reflect confounding
whereby a change in the underlying risk of fractures is temporally
associated with a decision to change a patient’s oral antidiabetic
therapy.Although itseemsimplausible that thedecisiontoprescribe
a thiazolidinedione would be related to a change in the underlying
risk of fracture, we conducted an analysis using exposure to
sulphonylureas as a control to investigate this further. This analysis
shows what happens to a patient’s risk of fracture on commencing a
new class of oral antidiabetic, and we found no evidence of an
increase in age-adjusted fracture risk. This finding suggests
confounding is unlikely to explain the results seen with thiazolidi-
nediones, and that the effect we report here may be a direct effect of
the drug. One would need to think of a form of time-varying
confounding that applied to commencing one form of oral
antidiabetic treatment (glitazones) but not to another (sulphonyl-
ureas) to be concerned that the thiazolidinedione results are due to
unmeasured time-varying confounding. The static results over time
for sulphonylureas also suggest the analysis has successfully adjusted
for age, otherwise we would expect to see the relative risk increasing
with sulphonylurea exposure period. In addition, the sensitivity
analysis restricting each patient’s observation period to the 2 y
before and after first thiazolidinedione prescription attempted to
remove some of the effect of age from the analysis and gave similar
results to the main analysis, which again suggests age was
adequately accounted for in these analyses.
We explored whether the choice of observation period could
have introduced bias to the results with sensitivity analyses.
Publication of the ADOPT trial in 2006 first highlighted fracture
as a possible risk with rosiglitazone and could have led to a change
in prescribing habits. An analysis restricted to observations before
publication had no material effect on our results. Secondly,
thiazolidinediones first became available in 2000; an analysis
restricted to observations from 2000 onwards also had no material
effect on the results, suggesting our choice of observation period
was robust to these factors.
Consideration must be given to other possible sources of bias.
Patients hospitalized following a fracture could continue thiazoli-
dinedione therapy but prescriptions issued in hospital would not be
recorded in the GPRD and such periods would therefore be missing
from our analysis. The resulting underestimate of thiazolidinedione
exposed time would lead to an overestimate of the risk during
exposed periods. We therefore looked for evidence of apparent
thiazolidinedione discontinuation postfracture. Less than 1% of
patients in our study discontinue their thiazolidinedione within 30 d
of a fracture, indicating this is unlikely to be a major source of bias.
Similarly, bias can be introduced with this form of case-series
analysis if a substantial proportion of the events of interest are fatal.
The exact cause of death can be difficult to establish using GPRD
records. Nonetheless we noted that death was recorded for 155
patients in this study. Of these, 88 had their final fracture before
starting a thiazolidinedione and only 11 (0.5%) had a fracture
during the 30 d prior to death. This result suggests fatal fractures
were rare in this study and therefore unlikely to lead to substantial
bias. The sensitivity analysis excluding patients who died confirms
this as the results were very similar to the main analysis.
Because the risk of fractures changes substantially as people
become older, it is important that our analysis adequately
controlled for the effect of age. We therefore adjusted for age at
the date of fracture, in single-year bands. The self-controlled case-
series method facilitates fine adjustments for age at every stage of
the analysis by stratifying follow-up time on a combination of drug
exposure and age. Of vital importance, patient age at first
thiazolidinedione prescription varied widely, and so although each
individual patient is older during their exposed period, both
exposed and unexposed states are fully represented in each age
band. We are confident that the increased risk of fractures
detected with thiazolidinediones is unlikely to be the effect of
residual confounding by age because the distinct lack of an
association with sulphonylurea exposure suggests our approach
successfully accounted for age.
The overall increased risk seen in our study is slightly smaller
than the near doubling of risk seen in clinical trials, although this
may reflect differences in treatment duration. We have found that
the relative risk of fracture appears to increase with treatment
duration, and the median treatment duration in the ADOPT study
was 4 y [5], compared with a mean duration of 2 y in our study.
Of most importance, the risk we have identified appears to be
nonspecific in terms of fracture site or gender, in contrast with the
trials that reported a risk predominantly in women, affecting bones
in the hand, arm, wrist, and foot [5,6]. However, these differences
may be due to a lack of power in the clinical trials to detect
fractures at less frequently affected sites, or in men, who generally
have a lower rate of fractures than women [16].
The recently published RECORD randomized clinical trial of
rosiglitazone versus metformin or a sulphonylurea also reported an
increased risk of fractures associated with rosiglitazone treatment
(overall risk ratio: 1.57, 95% CI 1.26–1.97) [17]. Fractures were
more common in women than men, and upper/lower limbs were
the sites most commonly affected. Very few hip and spine fractures
were reported, precluding firm conclusions about any effect of
glitazones at these sites. Although the study was not designed or
powered to study fractures, the results appear broadly consistent
with those reported here.
The large number of patients included in our study allowed us
to look in detail at the effect of treatment duration, and our results
suggest the increased risk of fractures is present within a year of
starting thiazolidinedione treatment, and the relative risk appears
to increase with continued treatment. This finding is of particular
relevance as the absolute risk of fractures with serious sequelae
(e.g., hip and vertebrae) increases dramatically with age [18], and
an additional increasing risk associated with thiazolidinediones is
likely to be of concern in patients at high baseline risk of fractures.
Of note, the age at first thiazolidinedione prescription was 10 y
greater in our study than the age at first exposure in the ADOPT
trial of rosiglitazone and so the absolute increase in fractures
would be substantially higher amongst this more elderly ‘‘real-
world’’ population than the absolute increase seen in clinical trials.
To demonstrate how our findings would affect patients with
different underlying fracture risks we have taken age- and sex-
specific fracture rates from the GPRD calculated by van Staa et al.
[16] and applied the relative rate for all fractures of 1.43 measured
in the present study. In men aged 50–55 y, treatment with a
thiazolidinedione could be expected to increase the rate of all
fractures by around 28 per 10,000 patient years. By contrast, in
women aged 80–85 y the rate of fractures could increase by 125
per 10,000 patient years.
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an increased risk of fractures associated with thiazolidinedione use
[18]. However, this study relied on comparisons between people
rather than within person. The reasons why someone might be
prescribed or not prescribed thiazolidinediones are likely to be
multiple and complex. In addition, it is likely that at least some of
the differences between people exposed and not exposed could be
related to the risk of future health outcomes, including fractures.
Between-person comparisons are therefore potentially prone to
selection bias and confounding due to factors that are unknown or
difficult to measure and control for. While broadly similar, the risk
estimates in the study by Meier et al. were somewhat higher than
those observed in our own study, possibly suggesting an element of
residual confounding in the case-control study. It is notable that in
the case-control study, only 47 of the people with fractures and
119 people in the control comparison group had been exposed to a
thiazolidinedione as the study focused on a narrow range of
fracture types. This result compares to the 1,819 people with
fractures who had been exposed to a thiazolidinedione included in
our study.
We have demonstrated an increased risk of fractures associated
with thiazolidinedione treatment. The increased risk was observed
with both rosiglitazone and pioglitazone, in both men and women,
and for a wide range of fracture sites including the hip. The risk
increases with treatment duration. These findings should be taken
into consideration in the wider debate surrounding the possible
risks and benefits of treatment with thiazolidinediones.
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Background. Worldwide, nearly 250 million people have
diabetes and this number is increasing rapidly, particularly in
developing countries. Diabetes is a chronic disease
characterized by dangerous amounts of sugar (glucose) in
the blood. Blood-sugar levels are normally controlled by
insulin, a hormone that the pancreas releases when blood-
sugar levels rise after eating (the digestion of food produces
glucose). Blood-sugar control fails in people with diabetes
because they make no insulin (type 1 diabetes) or because
the fat cells and muscle cells that usually respond to insulin
by removing sugar from the blood have become insulin
insensitive (type 2 diabetes). Type 1 diabetes is treated with
insulin injections; type 2 diabetes—the most common type
of diabetes—is controlled with diet, exercise, and
antidiabetic pills, drugs that help the pancreas make more
insulin (for example, sulfonylureas) or that make cells more
sensitive to insulin (for example, thiazolidinediones). Long-
term complications of diabetes include kidney failure,
blindness, and nerve damage, and an increased risk of
developing cardiovascular problems, including heart disease
and strokes.
Why Was This Study Done? Thiazolidinediones are widely
used to treat type 2 diabetes but, worryingly, these drugs
seem to increase people’s risk of developing cardiovascular
problems. In addition, they may increase the risk of bone
fractures although the evidence for this particular association
is limited. Given the large number of people with diabetes, it
is important to understand the benefits and risks of
thiazolidinedione treatment of diabetes as fully as possible.
In this self-controlled case-series study, therefore, the
researchers investigate the risk of fracture associated with
the use of rosiglitazone and pioglitazone (two
thiazolidinedione antidiabetic agents). A ‘‘self-controlled
case-series study’’ compares how often an event (in this
case, a fracture) occurs (the event’s ‘‘rate’’) in a population of
individuals during a period of time when the individuals are
not exposed to a medical intervention (in this case,
treatment with thiazolidinediones) to its rate during a
period when they are exposed to the intervention. Because
each person acts as their own control, this study design
helps to eliminate the possibility that unrecognized
characteristics that vary between people (‘‘confounders’’)
are responsible for differences in the event rate rather than
the intervention itself.
What Did the Researchers Do and Find? The researchers
identified 1,819 people aged 40 years or older with a
recorded fracture and at least one prescription for a
thiazolidinedione by searching the UK General Practice
Research Database, which contains personal and health
data for more than 6 million UK residents. They compared
these people’s fracture rate during periods when they were
taking a thiazolidinedione to their fracture rate when they
weren’t taking one of these drugs. After adjusting for age
(age is a potential confounder because the risk of fractures
increases with age and all the patients were older during
their exposed period than during their unexposed period),
the rate ratio for fracture at any site in patients during
thiazolidinedione-exposed periods compared with
thiazolidinedione-unexposed periods was 1.43. That is,
nearly one and half times as many fractures occurred when
people were taking thiazolidinediones than when they were
not taking these drugs. The association between taking
thiazolidinediones and the risk of fracture was similar in men
and women and at several fracture sites but increased with
the length of thiazolidinedione exposure.
What Do These Findings Mean? These findings suggest
that taking thiazolidinediones is associated with an increased
risk of fracture at a wide range of sites in both men and
women. They also suggest that the risk of fracture increases
with treatment duration. These findings do not prove that
thiazolidinediones cause fractures because, despite the self-
controlled case-series design of this study, it remains
possible that the people who have fractures share some
unknown characteristic that affects their chances of breaking
a bone. The accuracy of the findings is also dependent on
the quality of the data in the General Practice Research
Database. Nonetheless, these results are in keeping with the
findings of clinical trials and other observational studies,
suggesting they represent a real effect of treatment with
thiazolidinediones. Although it is not clear yet how
thiazolidinediones weaken bones, these findings need to
be included in the ongoing debate about the risks and
benefits of the treatment of type 2 diabetes with
thiazolidinediones.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000154.
N The International Diabetes Federation provides informa-
tion about all aspects of diabetes
N The US National Diabetes Information ClearingHouse
provides detailed information about diabetes (including
information on medicines for diabetes) for patients, health-
care professionals, and the general public (in English and
Spanish)
N The UK National Health Service also provides information
for patients and carers about type 2 diabetes (in several
languages)
N MedlinePlus provides links to further resources and advice
about diabetes and diabetes medicines (in English and
Spanish)
N Information about the UK General Practice Research
Database and about the self-controlled case-series method
is available
N More information is available where the research was done
at The London School of Hygiene & Tropical Medicine
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